Lakefront Biotherapeutics | GLPG - Ordinary Share Capital


Lakefront Biotherapeutics reported EUR65.66M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
argenx SE USD 62.54M 2.74M Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Biogen USD 146.7M 200K Sep/2025
Genmab DKK 61.44M 181K Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
GRIFOLS EUR 680.58M 6K Jun/2026
Hikma Pharmaceutical USD 221.89M 181.89M Dec/2025
Incyte USD 200.98M 1.03M Jun/2026
Merck EUR 434.78M 0 Jun/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026
UCB EUR 190.36M 365.15K Dec/2025
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026